StreetAlpha.app
Home › Stocks › GH

Guardant Health, Inc. (GH)

Healthcare
$143.28
▼ −0.52%
LAST CLOSE · NOV 17

Guardant Health offers blood and tissue tests for cancer screening, treatment selection and disease monitoring. It last closed at $143.28 on Nov 17, down 0.52% on the day. GH last reported earnings on Thu, Nov 5, 2026. The average 12-month price target from 8 analysts is $206.00 (+43.8% from the last close), with a high of $225.00 and a low of $190.00. Analyst consensus is Strong Buy, based on the latest ratings from 8 firms (8 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 18 whale options trades in GH, 44% of them bullish and 56% bearish. In the past 30 days there were 18 dark pool prints totaling $49.0M, the largest $11.6M.

AI Auto Pilots
Is GH in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$1.3B
+41.7% vs a year ago
Net income
−$485.1M
−37.9% margin
EPS (diluted)
−$3.68
Free cash flow
−$232.1M
−18.2% margin
Valuation
Market cap
$19.4B
135.3M shares
P/E
–
No P/E while losing money
Price to sales
15.2
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$1.0B
At Sep 30
Debt
$1.5B
At Sep 30
Shareholder equity
−$275.9M
Shares outstanding
135.3M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $373.7M$373.7MFY2021FY2022: $449.5M$449.5MFY2022FY2023: $563.9M$563.9MFY2023FY2024: $739.0M$739.0MFY2024FY2025: $982.0M$982.0MFY2025

From GH's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · After the close (AMC)
Reported EPS
-$0.29
vs -$0.75 est. · beat
Year-ago EPS
—
Not on file
Options-implied move
±17.3%
Priced in before that report
Analyst consensus
Strong Buy
Based on 8 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
8firms
8 Buy0 Hold0 Sell
Each firm's latest rating on GH in the past 90 days
Average 12-month target
$206.00
▲ 43.8% upside

Based on 8 analysts who set a price target on GH in the past 90 days. The average target is $206.00, with a high of $225.00 and a low of $190.00, compared with the last close of $143.28.

Low $190.00Avg $206.00High $225.00
Blue marker: last close $143.28
Highest target$225.00
Average target$206.00
Lowest target$190.00
Latest rating changes
Piper SandlerTarget lowered
Nov 10Buy$193 → $190
BTIGTarget raised
Oct 27Buy$195 → $210
Roth CapitalInitiated
Oct 23Buy$200
Morgan StanleyTarget raised
Oct 13Buy$185 → $200
BarclaysTarget raised
Oct 7Buy$200 → $220
DateFirmActionRatingPrice target
Nov 10Piper SandlerTarget loweredBuy$193 → $190
Oct 27BTIGTarget raisedBuy$195 → $210
Oct 23Roth CapitalInitiatedBuy$200
Oct 13Morgan StanleyTarget raisedBuy$185 → $200
Oct 7BarclaysTarget raisedBuy$200 → $220
Loading…

Technical Analysis

GH · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend, nearing oversold

The stock is 14% below its 20 day and 17% below its 50 day average. It is 7% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 34), near oversold. The nearest support is the swing low (Jul 29) at $140.86, and the nearest resistance the Pivot at $144.42.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityHigh, 6.5%/day
Key levels
$191.0552 week high+33.3%
$167.9550 day average+17.2%
$163.9120 day average+14.4%
$163.85100 day average+14.4%
$163.39Swing high (Nov 11)+14.0%
$147.81Pivot R1+3.2%
$144.42Pivot+0.8%
$143.28Last close
$140.86Swing low (Jul 29)−1.7%
$139.89Pivot S1−2.4%
$133.08200 day average−7.1%
$74.5552 week low−48.0%
Indicators
RSI (14)33.84Weak, oversold below 30Neutral
MACD-5.93Below its signal lineBearish
Stochastic20.1Middle of its rangeNeutral
ADX (14)21.3Weak trend
Williams %R-86.2Oversold below −80, overbought above −20Oversold
CCI (20)-123.9Oversold below −100, overbought above 100Oversold
Rate of change−18.1%Change over 10 sessionsBearish
ATR (14)$9.37Typical daily range, 6.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for GH

What happened before

See how GH did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Whale flow is mixed8 bullish and 10 bearish whale options trades in the last 90 days. See Whale Flow
November seasonalityHow GH usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How GH has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
18
Bullish
8
44%
Bearish
10
56%
Date span
Aug 28 – Nov 13
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
18
Notional
$49.0M
Largest print
$11.6M
Loading…

GH Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲388 buying vs 276 selling
  • ▼Held by funds -5.2 pts
  • ▲Funds holding +67
  • ▼Superinvestors: 2 added, 3 cut
  • ▼Put/call 1.87 to 5.52
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding677610+11.0%
In funds' top 102219+15.8%
Held by funds98.5%103.8%−5.2 pts
New / increased139 / 249156 / 202+8.4%
Reduced / sold out209 / 67179 / 45+23.2%
Put/call ratio5.521.87+195.0%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See GH institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GH is in one of them and how their past GH trades turned out.

GH in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered GH in an article yet. Here's the latest on the wider market.

GH Congress Trades

All congress trades →
Trades, 12 months
2
Buys
2
100%
Sells
0
0%
People
2
Last filed Oct 20
Who traded GH · since 2020
Latest 5 filings of 12
$15K – $50KTraded Sep 28, 2026Filed Oct 20, 2026
$1K – $15KTraded Nov 21, 2025Filed Dec 1, 2025
$1K – $15KTraded Feb 28, 2022Filed Mar 3, 2022
$1K – $15KTraded Jan 13, 2022Filed Feb 1, 2022
$1K – $15KTraded Dec 22, 2021Filed Jan 1, 2022
PersonTypeAmountTradedFiledDelay
Jonathan JacksonD · ILBuy$15K – $50KSep 28, 2026Oct 20, 202622 d
Sheldon WhitehouseD · RIBuy$1K – $15KNov 21, 2025Dec 1, 202510 d
Don BeyerD · VASell$1K – $15KFeb 28, 2022Mar 3, 20223 d
Don BeyerD · VASell$1K – $15KJan 13, 2022Feb 1, 202219 d
Don BeyerD · VASell$1K – $15KDec 22, 2021Jan 1, 202210 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Guardant Health

Guardant Health is a precision oncology company based in Palo Alto, California. It offers blood and tissue tests that help doctors choose treatments for patients with advanced cancer, monitor for residual or returning disease after early stage treatment, and screen adults for colorectal cancer. The company also provides its tests and AI-based data analytics tools to biopharmaceutical companies running clinical studies and drug development. Its customers include oncologists, physicians, health systems and drug developers.

Headquarters
Palo Alto, CA